DOYLESTOWN, Pa., April 10 (UPI) -- Quigley said Monday it plans to launch phase 1 and 2 studies of QR-333, a treatment for diabetes complications.
The company said the Food and Drug Administration approved its phase 2 study of the topical compound that is intended as a treatment for diabetic peripheral neuropathy.
"Patient screening and enrollment will begin immediately for the first of two human trials designed to determine the safety pharmacokinetics of ... QR-333," Quigley said in a statement. "A Phase 2b dose ranging study will commence after the completion of the pharmacokinetic study."
The company said an original proof-of-concept study conducted in France demonstrated the topical compound improved quality of life and key symptoms of diabetic peripheral neuropathy. The study participants used QR-333 saw 67 percent of their symptoms improve, according to Quigley.
